Companies Dominating the Oculopharyngeal Muscular Dystrophy Landscape
- Bristol-Myers Squibb
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BioMarin
- Sarepta Therapeutics
- Benitec Biopharma Inc
- Bioblast Pharma
- PTC Therapeutics
- NS Pharma
- Nobel pharma Co. Ltd
- Santhera Pharmaceuticals
- Pfizer Inc.
- Fibrinogen
- GSK
Browse Key Market Insights with Data Illustration:
In the News
- 16 February 2024 - Sarepta Therapeutics Inc., the leader in precision genetic medicine for rare diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficacy supplement to the Biologics License Application. The FDA has granted the Efficacy Supplement a Priority Review with a review goal date of June 21, 2024. The Agency has also confirmed they are not planning to hold an advisory committee meeting to discuss the supplement.
- Monday, February 05, 2024 - The American Cancer Society (ACS) and Pfizer Inc. announced the launch of “Change the Odds: Uniting to Improve Cancer Outcomes™,” a three-year initiative to bridge the gap in cancer care disparities. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, and patient support and comprehensive navigation. “Change the Odds” will initially focus on breast and prostate cancer in medically underserved communities, with the potential to expand to additional cancer types.
